Oncocyte (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, on Wednesday announced it has been named as one of the 2020 Best Places to Work in Orange County. Oncocyte ranked number four out of 40 in the medium-size company category. A project of the Orange County Business Journal and Best Companies Group, the awards program was created in 2009. “Great technologies and great strategies don’t do great things; great people accomplish great things,” said Ron Andrews, CEO of Oncocyte. “While our world of molecular diagnostics can be extremely technically oriented, having the right employees who can combine scientific brilliance with a heart for the patients we serve is essential to our success. We are blessed to have an incredibly talented, mission-oriented team who show up each day with humility and genuine care for one another. This combination is a foundational organizational attribute given the pace at which we expect everyone to work. We are very honored to be ranked in this year’s list given how young we are as a company here in Orange County and owe a big ‘thank you’ to our dedicated employees!”
To view the full press release, visit https://ibn.fm/4UT6r
About Oncocyte Corporation
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The company’s proprietary tests and pharmaceutical company services aim to save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. Oncocyte’s tests and services present multiple opportunities to advance cancer care while driving the growth of its revenue. The company recently launched DetermaRx(TM), a treatment stratification test to identify early-stage lung cancer patients who are at high risk for cancer recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO(TM), a gene expression test that identifies patients who are more likely to respond to checkpoint inhibitor immunotherapies. The company also plans to launch Therasure(TM)-CNI MONITOR, a blood-based immune therapy monitoring test. Oncocyte’s pharmaceutical company services help pharmaceutical companies to develop new cancer treatments, many of which may be linked to Oncocyte’s diagnostic tests. For more information about the company, visit www.Oncocyte.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork